Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer

Author's Avatar
Jun 16, 2020
Article's Main Image

monarchE demonstrates positive results in Phase 3 study of 5,637 people whose early breast cancer is at a high risk of recurrence

Verzenio given with standard endocrine therapy showed improvement compared to standard endocrine therapy alone

Verzenio is the only CDK4 & 6 inhibitor to demonstrate statistically significant improvement in invasive disease-free survival in this setting

Lilly will submit data from monarchE to regulatory authorities around the world

PR Newswire